Published in final edited form as:

Cancer Treat Res Commun. 2016 ; 9: 139–142. doi:10.1016/j.ctarc.2016.09.005.

TELEHEALTH ALLOWS FOR CLINICAL TRIAL PARTICIPATION AND MULTIMODALITY THERAPY IN A RURAL PATIENT WITH STAGE 4 NON-SMALL CELL LUNG CANCER

James M. Clark, MD^a, Laurence J. Heifetz, MD^b, Daphne Palmer, MD^c, Lisa M. Brown, MD, MAS^a, David T. Cooke, MD^a, and Elizabeth A. David, MD^{a,d,*}

^aSection of General Thoracic Surgery, Department of Surgery, UC Davis Medical Center, 2315 Stockton Blvd, Sacramento, CA 95817, USA

^bDepartment of Medical Oncology, Tahoe Forest Cancer Center, 10121 Pine Ave, Truckee, CA 96161, USA

^cDepartment of Radiation Oncology, Tahoe Forest Cancer Center, 10121 Pine Ave, Truckee, CA 96161, USA

^dHeart Lung Vascular Center, David Grant Medical Center, Travis AFB, 101 Bodin Cir, Fairfield CA 94533, USA

Abstract

Oligometastatic non-small cell lung cancer (NSCLC) has a poor prognosis for rural patients with traditional therapies. Implementation of multi-modality systemic therapy in conjunction with surgical resection can dramatically improve overall survival, leading to clinical complete remission. The currently accepted indications for resection in oligometastatic NSCLC include brain and adrenal metastases. Rural populations are known to have disparities in care of complex malignancies and the use of telehealth has been shown to improve outcomes. We present a case of a rural patient with stage IV NSCLC, who was able to participate in two clinical trials, undergo trimodality therapy, and remain disease-free for 18 months, whose care was facilitated via telehealth video conferencing with a tertiary care center.

Keywords

telemedicine; non-small cell lung cancer (NSCLC); clinical trial; rural health

*Corresponding author. Elizabeth A David MD, FACS 2221 Stockton Blvd, Rm 2121 Sacramento, CA, 95817. 916-734-3861; 916-734-3066 (fax); Eadavid@ucdavis.edu.

Conflict of Interest Statement

The authors have stated that they have no conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

INTRODUCTION

Non-small cell lung cancer (NSCLC) remains the highest mortality malignancy throughout the developed world, in large part because most patients have advanced stage disease at presentation.¹ Nearly 50% of NSCLC patients have distant metastases on presentation, with an associated 5 year survival less than 5% in stage IV patients.^{1,2} Survival outcomes are reduced in patients from rural environments, often due to delays in diagnosis, treatment, and follow up as well as unavailability of advanced care including multimodality treatment options and enrollment in clinical trials.^{3–6} Systemic therapy is the primary method of treatment in these patients with local or distant metastatic disease, and when combined with appropriate surgical resection can lead to significantly improved survival rates.⁷

Hellman and Weichselbaum described the term oligometastasis in 1995, which is now synonymous with 1–5 isolated distant metastases.⁸ Outcomes in NSCLC patients with oligometastases are superior to widely metastatic disease but remain poor, and data is limited to retrospective single institution series.⁹ The current National Comprehensive Cancer Network (NCCN) guidelines currently recommend surgical resection of lung primary tumors in oligometastatic disease only in those patients with either isolated brain or adrenal metastases.¹⁰ There is a paucity of evidence for resection of primary lung tumors in patients with oligometastatic disease to other sites such as to the bones, vertebrae, liver, distant lung sites, and soft tissue, with variable success.^{11–14}

It is well known that cancer patients with limited access to high quality specialized medical care have worse outcomes compared to their counterparts near large medical centers with medical and surgical oncologic specialists.^{4,6,15} In order to surmount the challenge of providing such rural patients with optimal multidisciplinary oncologic care, many centers have turned to telemedicine via videoconferencing.^{16–18} Initial studies from multiple institutions have demonstrated that patient discussion in multidisciplinary video tumor boards improves patient satisfaction, provides more patients access to definitive surgical care, and does not significantly delay oncologic therapies.^{16,17,19,20} However, these data are limited in an era where more and more institutions are using telemedicine to facilitate the care of these advanced stage cancer patients.²¹

We present a report of a rural patient with T2N2M1b NSCLC with oligometastasis to the femur who participated in two therapeutic clinical trials, underwent multimodality treatment with chemoradiation at the local rural cancer center, and surgical intervention at the partnering tertiary care center through the successful coordination of telemedicine. The patient has been without evidence of disease for 18 months.

PRESENTATION OF CASE

A previously healthy 59 year old Caucasian woman with a distant 2 pack-year smoking history was diagnosed with clinical stage IIIA (T2aN2M0) adenocarcinoma primary lung cancer in May 2013 after presenting with shoulder pain (Figure 1). A computed tomography (CT) scan of the chest revealed a 4.8 cm pulmonary mass in the left upper lobe encasing the left upper lobe bronchus, as well as a suspicious 1.8 cm lymph node within the left

aortopulmonary window. Core needle biopsy confirmed well-differentiated adenocarcinoma in-situ. Positron emission tomography (PET) imaging was concerning for metastases in mediastinal and left hilar nodes (Figure 1a). Brain metastases were excluded with magnetic resonance imaging (MRI). Her case was discussed during the scheduled weekly multidisciplinary telehealth tumor board with the National Cancer Institute Comprehensive Cancer Center (NCI-CCC) partner. The consensus recommendation was invasive mediastinal staging, which was subsequently performed at the partnering NCI-CCC. Her mediastinum was staged with video cervical mediastinoscopy in June 2013; ten lymph nodes were negative for malignancy. At this time she began neoadjuvant chemoradiation at her local rural cancer center as part of planned trimodality therapy for stage IIIA disease. Her chemotherapy regimen consisted of two cycles of cisplatin and etoposide concurrently with 50.4 Gy given in 28 fractions of radiation to the involved lung and mediastinum.

A restaging PET scan was completed in September 2013, which showed a decrease in primary tumor size to 4.5 cm and resolution of fludeoxyglucose (FDG) avid nodal disease. However a new 1.0 cm focus of activity in the right femur was identified and CT-guided biopsy demonstrated bone metastasis (Figure 1b). She subsequently completed 2 cycles of carboplatin, paclitaxel, and bevacizumab induction prior to 36 Gy given in 12 fractions of radiation to the right femur. At this point, an EGFR mutation was identified in the primary tumor and after multidisciplinary discussion via telehealth, she was enrolled in therapeutic clinical trials for both zoledronic acid and erlotinib in April 2014 at her local cancer center. For the remainder of 2014, imaging revealed resolution of her femur lesion and intrathoracic disease stability and her case was represented at multidisciplinary tumor board via telehealth for consideration of resection of her primary tumor.

In February 2015, she underwent left upper lobe lobectomy via thoracotomy secondary to central tumor location at the NCI-CCC partner. Her surgical pathology revealed a 0.6 cm mass with <10% viable residual tumor, negative margins, and 13 lymph nodes negative for tumor (ypT1aN0M0). As of August 2016, she is without evidence of disease and she remains on the zoledronic acid and erlotinib protocols. Her only complication was a right hip fracture sustained after a ground level fall while hiking that required open reduction and internal fixation. She otherwise has been in excellent health with the functional capacity to continue her hiking.

DISCUSSION

There are a significant number of surgical case series describing the treatment of oligometastatic NSCLC with isolated brain or adrenal metastases. These studies have shown a median overall survival of 7 to 27 months.^{7,9,11–14,22} However, there is insufficient evidence on the surgical outcomes of oligometastatic NSCLC patients with other metastatic sites, likely driven by the lack of NCCN guideline support for surgical resection in these patients. Recently there have been increasing reports on the treatment of patients with oligometastases to the bones, vertebra, liver, intrapulmonary sites, and other soft tissue sites. (Table 1.) Median overall survival in these patients ranges from 13 to 21 months, with between 15 to 30% of patients achieving complete remission such as was seen in our patient. The largest case series reported by Griffioen et al. had only 18% of patients with bony

oligometastases, and 62% of their patients ultimately died of their cancer with a median overall survival of 13 months.⁷ Up to 59% of their patients had brain oligometastases which significantly worsens the overall prognosis in these NSCLC patients.^{23–25} As such, the survival seen in case series with a significant proportion of patients with brain oligometastases may not generalize well to patients such as our own with an isolated extracranial oligometastasis.

A prospective case series by De Ruyscher et al. described 18% of patients having bony oligometastases and a median overall survival of 13 months.¹⁴ Only 23% of their patients underwent resection of the primary tumor, limiting the applicability of this data to patients like our own who had successful downstaging of her disease with neoadjuvant therapy to nodal and metastatic negative disease prior to surgery. However, this growing body of literature has influenced the recent European Society for Medical Oncology (ESMO) 2014 guidelines which emphasizes a potential role for radical resection in NSCLC patients with extracranial oligometastatic sites.²⁶ The ESMO guidelines stress the need to enroll these patients in prospective treatment trials to better guide treatment protocols.

Our case report describes the successful treatment of a patient with stage 4 NSCLC with oligometastasis to the femur with neoadjuvant chemoradiation and surgical resection. Her case is novel in that her nodal and bony metastases responded completely to induction therapy, allowing for sustained complete remission post-operatively. She benefited from successful use of multidisciplinary care via telehealth that involved surgical therapy at a tertiary academic medical center in coordination with outpatient chemoradiation at a community cancer treatment center. Her case was discussed in a telehealth conference at every major decision point in her care, which allowed her local oncologists to continue optimal management of her disease close to home in her community. It is well known that geographic distance from urban advanced care centers has a negative impact on cancer survival, leading to limited access to appropriate screening, later stages at diagnosis, and worse overall survival.^{3,21,27–29} Multiple Australian studies have demonstrated that lung cancer patients who live further from specialist hospitals with thoracic surgeons on staff have higher cancer related mortality rates.^{4,15} This is likely due to the fact that patients admitted to specialist hospitals were more likely to receive a resection, which was similarly associated with improved survival. A population based study of NSCLC patients in the UK shows that greater distance from facilities with a thoracic oncology team lead to 1.7 times higher odds of not receiving surgical treatment irrespective of stage at diagnosis, and that those patients initially seen in a thoracic surgical center were 1.5 times more likely to receive definitive surgical resection.^{5,6} There is similar geographical data in colorectal cancer showing that urban patients are 1.4 times more likely to have appropriate screening for colorectal cancer than their rural counterparts, leading to a higher incidence of advanced stage cancer at time of diagnosis for rural patients as opposed to those in urban areas.^{28,29}

In order to surmount these discrepancies in urban and rural cancer patients, many healthcare systems have developed multidisciplinary tumor teleconferences to link community cancer treatment centers with regional specialist hospitals. Seeber et al. describe the development of such a telehealth tumor conference in Austria.¹⁶ Implementation of this videoconference system over an eight year period allowed multidisciplinary discussion of over 200 patients,

ultimately resulting in increased use of radiotherapy as compared to before beginning the videoconference system. Videoconference technology is being increasingly used to facilitate multidisciplinary tumor boards with positive results in multiple institutions.^{17,18,20} The concern some hold with the development of such integrated systems is that it could lead to delays in care. Leo et al. demonstrated in a French population of lung cancer patients that despite an average delay to treatment of 4 weeks, their patients that were discussed in multidisciplinary tumor boards and underwent the planned therapy discussed at the tumor board received timely care with a nonsignificant increase in one year survival ($p=0.07$).³⁰ Chekerov et al. describe the successful use of a fully online integrated tumor board for discussion of gynecologic cancer patients.³¹ Stevenson et al. discuss the implementation of a virtual tumor board at Duke University for the treatment of their lung cancer patients, 85% of which receive their care in community cancer centers.¹⁹ They encountered many of the same initial challenges our institution faced in establishing such a conference for telemedicine, including technological hurdles in connecting multiple cancer centers. Once the system was well established, buy-in from providers in multiple disciplines and medical centers helped bolster the conference as a staple in the treatment of their complex lung cancer patients. We have had similar successes in coordinating lung cancer patients' care between community cancer centers and our central academic medical center.

Our patient's rural location did not preclude her from enrollment in two therapeutic clinical trials which have supported her long-term disease remission. It is important to explore how telehealth is being successfully used to bring excellent specialized care to rural patients, and how these lessons can be implemented in larger patient populations. The traditionally poor oncologic outcomes experienced in these rural patients may be surmounted with appropriate use of multidisciplinary tumor board discussions and appropriate planning and follow-up as coordinated with telehealth modalities.

CONCLUSION

There may be a role for aggressive neoadjuvant chemoradiation in conjunction with definitive surgical resection in stage IV NSCLC patients with oligometastatic disease to sites outside of the brain and adrenal glands. The barriers to providing optimal cancer care to rural populations can be addressed with use of telehealth and tumor board conferences for multidisciplinary coordination of care. Other patients like ours may benefit from aggressive treatment of their extracranial and extra-adrenal oligometastatic lung cancers, such that further prospective trials enrolling these patients are needed.

Acknowledgments

Funding sources

The work was supported by the National Center for Advancing Translational Sciences, National Institutes of Health [grant number UL1 TR000002]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

References

1. Howlader, N.Noone, AM.Krapcho, M.Garshell, J.Miller, D.Altekruse, SF.Kosary, CL.Yu, M.Ruhl, J.Tatalovich, Z.Mariotto, A.Lewis, DR.Chen, HS.Feuer, EJ., Cronin, KA., editors. SEER Cancer Statistics Review, 1975–2012, based on November 2014 SEER data submission. National Cancer Institute; Bethesda, MD: 2015. at http://seer.cancer.gov/csr/1975_2012/ [Accessed April 1, 2016]
2. Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. *Thorax*. 2013; 68:551–64. [PubMed: 23399908]
3. Emery JD, Gray V, Walter FM, et al. The Improving Rural Cancer Outcomes (IRCO) Trial: a factorial cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural patients with cancer in Western Australia: a study protocol. *BMJ Open*. 2014; 4:e006156.
4. Tracey E, McCaughan B, Badgery-Parker T, Young J, Armstrong B. Survival of Australian lung cancer patients and the impact of distance from and attendance at a thoracic specialist centre: a data linkage study. *Thorax*. 2015; 70:152–60. [PubMed: 25074705]
5. Rich AL, Tata LJ, Free CM, et al. Inequalities in outcomes for non-small cell lung cancer: the influence of clinical characteristics and features of the local lung cancer service. *Thorax*. 2011; 66:1078–84. [PubMed: 21785158]
6. Crawford SM, Sauerzapf V, Haynes R, Zhao H, Forman D, Jones AP. Social and geographical factors affecting access to treatment of lung cancer. *Br J Cancer*. 2009; 101:897–901. [PubMed: 19690543]
7. Griffioen GH, Toguri D, Dahele M, et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. *Lung Cancer*. 2013; 82:95–102. [PubMed: 23973202]
8. Hellman S, Weichselbaum RR. Oligometastases. *J Clin Oncol*. 1995; 13:8–10. [PubMed: 7799047]
9. Pfannschmidt J, Dienemann H. Surgical treatment of oligometastatic non-small cell lung cancer. *Lung Cancer*. 2010; 69:251–8. [PubMed: 20537426]
10. National Comprehensive Cancer Network. [Accessed April 1, 2016] NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. 2016. at http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
11. Congedo MT, Cesario A, Lococo F, et al. Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience. *J Thorac Cardiovasc Surg*. 2012; 144:444–52. [PubMed: 22713303]
12. Collaud S, Stahel R, Inci I, et al. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. *Lung Cancer*. 2012; 78:234–8. [PubMed: 23040415]
13. Khan AJ, Mehta PS, Zusag TW, et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). *Radiother Oncol*. 2006; 81:163–7. [PubMed: 17050016]
14. De Ruysscher D, Wanders R, van Baardwijk A, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). *J Thorac Oncol*. 2012; 7:1547–55. [PubMed: 22982655]
15. Vinod SK, O'Connell DL, Simonella L, et al. Gaps in optimal care for lung cancer. *J Thorac Oncol*. 2008; 3:871–9. [PubMed: 18670305]
16. Seeber A, Mitterer M, Gunsilius E, et al. Feasibility of a multidisciplinary lung cancer videoconference between a peripheral hospital and a comprehensive cancer centre. *Oncology*. 2013; 84:186–90. [PubMed: 23328311]
17. Marshall CL, Petersen NJ, Naik AD, et al. Implementation of a regional virtual tumor board: a prospective study evaluating feasibility and provider acceptance. *Telemed J E Health*. 2014; 20:705–11. [PubMed: 24845366]
18. El Saghir NS, Keating NL, Carlson RW, Khoury KE, Fallowfield L. Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide. *Am Soc Clin Oncol Educ Book*. 2014:e461–6. [PubMed: 24857140]

19. Stevenson MM, Irwin T, Lowry T, et al. Development of a virtual multidisciplinary lung cancer tumor board in a community setting. *J Oncol Pract.* 2013; 9:e77–80. [PubMed: 23942505]
20. Shea CM, Teal R, Haynes-Maslow L, et al. Assessing the feasibility of a virtual tumor board program: a case study. *J Healthc Manag.* 2014; 59:177–93. [PubMed: 24988672]
21. Flodgren G, Rachas A, Farmer AJ, Inzitari M, Shepperd S. Interactive telemedicine: effects on professional practice and health care outcomes. *Cochrane Database Syst Rev.* 2015:CD002098. [PubMed: 26343551]
22. Bonnette P, Puyo P, Gabriel C, et al. Surgical management of non-small cell lung cancer with synchronous brain metastases. *Chest.* 2001; 119:1469–75. [PubMed: 11348955]
23. Qin H, Wang C, Jiang Y, Zhang X, Zhang Y, Ruan Z. Patients with single brain metastasis from non-small cell lung cancer equally benefit from stereotactic radiosurgery and surgery: a systematic review. *Med Sci Monit.* 2015; 21:144–52. [PubMed: 25579245]
24. Flannery TW, Suntharalingam M, Regine WF, et al. Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. *Int J Radiat Oncol Biol Phys.* 2008; 72:19–23. [PubMed: 18280058]
25. Gray PJ, Mak RH, Yeap BY, et al. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. *Lung Cancer.* 2014; 85:239–44. [PubMed: 24974152]
26. Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2014; 25(Suppl 3):iii27–39. [PubMed: 25115305]
27. Baade PD, Youlden DR, Coory MD, Gardiner RA, Chambers SK. Urban-rural differences in prostate cancer outcomes in Australia: what has changed? *Med J Aust.* 2011; 194:293–6. [PubMed: 21426283]
28. Ojinnaka CO, Choi Y, Kum HC, Bolin JN. Predictors of Colorectal Cancer Screening: Does Rurality Play a Role? *J Rural Health.* 2015; 31:254–68. [PubMed: 25599819]
29. Baade PD, Dasgupta P, Aitken J, Turrell G. Geographic remoteness and risk of advanced colorectal cancer at diagnosis in Queensland: a multilevel study. *Br J Cancer.* 2011; 105:1039–41. [PubMed: 21897391]
30. Leo F, Venissac N, Poudenx M, Otto J, Mouroux J. Groupe d'Oncologie Thoracique A. Multidisciplinary management of lung cancer: how to test its efficacy? *J Thorac Oncol.* 2007; 2:69–72. [PubMed: 17410013]
31. Chekerov R, Denkert C, Boehmer D, et al. Online tumor conference in the clinical management of gynecological cancer: experience from a pilot study in Germany. *Int J Gynecol Cancer.* 2008; 18:1–7.

Fig. 1a

Fig. 1b

Fig. 1c **Fig 1a–b.**

(a) Initial positron emission tomography (PET) scan on 6/4/13 showing left upper lobe pulmonary mass and mediastinal/hilar lymph nodes. (b) Repeat PET scan on 9/12/13 after neoadjuvant chemoradiation showing an interval decrease in pulmonary mass size and lymphadenopathy as well as a new foci in the right femur (denoted by solid arrow). (c) Most recent PET scan on 3/17/16 showing no evidence of residual tumor or metastases.

Selected review of the literature of outcomes for oligometastatic NSCLC to sites beyond brain and adrenal glands.

Table 1

Investigator	Congedo et al.	Collaud et al.	De Ruysscher et al.	Griffioen et al.	Khan et al.
Patients (n)	53	29	39	61	23
Mean age (years)	61	62	62	62	
Gender (% male)	60.3	68.9	46.2	51	43.5
Histology (%)					
Adenocarcinoma	75.5	72.4	33.3	78.7	
Squamous	15.1	6.9	20.5	8.2	
Other	9.4	20.7	46.2	13.1	
Oligometastasis location (%)					
Brain	70.9	65.5	43.9	59.0	60.9
Adrenal	14.5	6.7	10.3	6.6	8.7
Bone	5.5		17.9	18.0	8.7
Vertebra	5.5				
Liver	1.8		2.6		
Intrapulmonary		27.6	10.3	6.6	13.0
Soft tissue			5.1	3.3	4.3
Response (%)					
No evidence of disease	26.4		15.4		30.4
Alive with disease	15.1				21.7
Died of disease	56.6			62.3	47.8
Died of other cause	1.9				
Median overall survival (months)	19	20.5	13.5	13.5	20